SCHEMBL15067359

SCHEMBL15067359

Cc1ccc2c(Nc3ccccc3)nccc2c1NC(=O)c1csc2c(N)ncnc12

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 13/20 0.84
RAF1 P04049 11/20 0.84
CSF1R P07333 11/20 0.84
DDR2 Q16832 6/20 0.84
DDR1 Q08345 5/20 0.84
ARAF P10398 1/20 0.71
MELK Q14680 2/20 0.41
FGFR1 P11362 1/20 0.41
KDR P35968 1/20 0.41
TEK Q02763 1/20 0.41
PLK4 O00444 1/20 0.40
PDPK1 O15530 1/20 0.40
DYRK3 O43781 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
CHEK2 O96017 1/20 0.40
LCK P06239 1/20 0.40
CDK1 P06493 1/20 0.40
FES P07332 1/20 0.40
LYN P07948 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31406752 1.00 BRAF (0.84) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL15065801 0.93 BRAF (0.87) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL15066865 0.93 BRAF (0.84) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL21372404 0.92 BRAF (0.87) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL15067385 0.92 BRAF (0.85) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL31061586 0.91 BRAF (1.00) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL15066024 0.91 BRAF (0.84) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL15066998 0.91 BRAF (1.00) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL16303091 0.91 BRAF (0.84) BRAFRAF1CSF1RDDR2DDR1
SCHEMBL15067512 0.91 BRAF (1.00) BRAFRAF1CSF1RDDR2DDR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3617213-B1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARMACEUTICAL CO LTD (KR) 2025-02-19 EP disclosed
EP-3617213-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES Hanmi Pharm. Co., Ltd. (KR) 2020-03-04 EP disclosed
EP-2797927-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM IND CO LTD (KR) 2019-09-25 EP disclosed
EP-2797927-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM IND CO LTD (KR) 2019-09-25 EP disclosed
US-RE47451-E1 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO. LTD. (KR) 2019-06-25 US disclosed
US-RE47451-E1 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO. LTD. (KR) 2019-06-25 US disclosed
US-9156852-B2 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO., LTD (KR) 2015-10-13 US disclosed
US-9156852-B2 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO., LTD (KR) 2015-10-13 US disclosed
US-20140371219-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM. CO., LTD (KR) 2014-12-18 US disclosed
US-20140371219-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM. CO., LTD (KR) 2014-12-18 US disclosed
EP-2797927-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES Hanmi Pharm. Co., Ltd. (KR) 2014-11-05 EP disclosed
WO-2013100632-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM CO., LTD. (KR) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371219-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES TK1, DTYMK, MAP4K2 BRAF 190/4885RAF1 148/4885CSF1R 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.